Successful Treatment With Erlotinib After Gefitinib-Related Severe Hepatotoxicity
Authors:
- 10 June 2010
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (17) , e273-e274
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Liver Toxicity After Treatment With Gefitinib and Anastrozole: Drug-Drug Interactions Through Cytochrome p450?Journal of Clinical Oncology, 2006
- CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase InhibitorsJNCI: Journal of the National Cancer Institute, 2006
- Promising New Treatment Schedule for Gefitinib Responders After Severe Hepatotoxicity With Daily AdministrationJournal of Clinical Oncology, 2006
- METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERSDrug Metabolism and Disposition, 2006
- Side Effects Related to Cancer TreatmentJournal of Clinical Oncology, 2005
- Cytochrome P450-dependent metabolism of gefitinibXenobiotica, 2005
- Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorJournal of Clinical Oncology, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003